Christopher Ogden - 16 Mar 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
SVP, Finance and Accounting
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
Issuer symbol
CTMX
Transactions as of
16 Mar 2023
Net transactions value
-$1,021
Form type
4
Filing time
20 Mar 2023, 18:43:35 UTC
Previous filing
06 Feb 2023
Next filing
19 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Sale $1,021 -516 -1.3% $1.98 37,772 16 Mar 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units.
F2 Includes 30,466 restricted stock units.